NovAccess Global, BCN Biosciences partner for immunotherapy platform

NovAccess Global announced the signing of a Letter of Intent and formation of a partnership with BCN Biosciences to expand its immunotherapy platform. Utilizing BCN’s small molecule drug BCN057, developed with support from the National Institutes of Health and in collaboration with the University of California Los Angeles, NovAccess Global has begun the development of a fourth generation of its novel brain tumor immunotherapy TLR-AD1, targeting glioblastoma. Awarded Orphan Drug Status by the U.S. Food and Drug Administration in 2022, TLR-AD1 improves the ability of specialized blood cells, known as Dendritic Cells, to recognize tumors. These specialized blood cells then provide a ‘zip code’ to the immune system improving its ability to seek out and destroy tumor cells in the body. While TLR-AD1 is the most advanced technology to enhance DC immunotherapy, a combination therapy leveraging BCN057 could further enhance DC tumor recognition as well as increase DC yield from patients’ blood. The partnership between NovAccess Global and BCN provides a unique opportunity to further develop BCN057 in combination with TLR-AD1 to benefit patients with CNS cancer and potentially other cancer tumor types. The partnership with BCN will further strengthen the IP portfolio supporting NovAccess Global’s 4th generation of TLR-AD1. This partnership will increase opportunities for third-party licensing of NovAccess Global’s drug platform to pharmaceutical companies active in developing new classes of therapies to compete in the global immune oncology market which today exceeds more than $100 billion a year.